Nucleoside transporters in kidney mediate renal re-absorption and secretion of nucleosides. Using RT-PCR, we demonstrated mRNAs encoding hENT1, hENT2, hCNT1, hCNT2 and hCNT3 in both cortex and medulla. Immunoblotting with crude membrane preparations revealed abundant hENT1 and hCNT3 in both cortex and medulla, and little, if any, hENT2, hCNT1 or hCNT2, indicating that the latter were either absent or below limits of detection of immunoassays. hENT1 immunostaining was observed on apical surfaces of proximal tubules and on both apical and basal surfaces of thick ascending loops of Henle and collecting ducts. Prominent hCNT3 immunostaining was observed on apical surfaces of proximal tubules, and thick ascending loops of Henle in addition to some cytoplasmic staining. and low levels of hENT2 activities. The presence of (i) transcripts for hENT1/2 and hCNT1/2/3 and the hENT1 and hCNT3 proteins in human kidneys and (ii) hENT1, hENT2 and hCNT3 activities in cultured proximal tubule cells suggest involvement of hENT1, hCNT3 and possibly also hENT2 in renal handling of nucleosides and nucleoside drugs.
Introduction:
Uptake and release of physiological nucleosides and most nucleoside drugs in human (h) cells are dependent on the activity of one or more members of two families of nucleoside transporters, the equilibrative and concentrative nucleoside transporters (hENTs, hCNTs) (2, 7) . Two of the four known hENTs have broad permeant selectivities and wide tissue distributions (17) and are functionally distinguished by their relative sensitivities to inhibition by nitrobenzylmercaptopurine ribonucleoside (NBMPR) as either highly sensitive (hENT1) or relatively insensitive (hENT2). Although both transporters are inhibited by dipyridamole, dilazep and draflazine, hENT1 is much more susceptible than hENT2. The other two hENTs (hENT3, hENT4) are more specialized; hENT3 is a broadly selective organellar transporter and hENT4 transports adenosine and monoamines (3) . hCNTs are found primarily in specialized tissues, including intestine, kidney, liver and choroid plexus (2) . Three different transporters (hCNT1, hCNT2, hCNT3) have been identified by molecular cloning (41, 43, 44, 52) . hCNT1, hCNT2 and hCNT3 mediate, respectively, pyrimidine-nucleoside selective, purinenucleoside selective and broadly selective nucleoside-transport activities.
Pharmacokinetic evidence suggests that some nucleosides are actively reabsorbed and secreted by the kidney (23, 39). Adenosine, a regulatory nucleoside that acts through binding to purinergic receptors, is found in plasma and its re-absorption in human kidney has been demonstrated. Several nucleosides have been shown in studies with rodents to be secreted by kidney, and it has been suggested that toxic nucleosides (e.g., 2 -deoxyadenosine) are selectively eliminated by renal secretion (24, 38) .
Renal re-absorption and secretion appear to involve different transport systems, since renal reabsorption of adenosine in mice was unaffected by classical nucleoside transport inhibitors (e.g., NBMPR and dipyridamole), whereas renal secretion of 2 -deoxyadenosine and 5 -deoxy-5 -Page 3 of 40 fluorouridine was decreased by treatment with these inhibitors (39) . There is also a growing body of evidence that organic cation transporters may be involved in renal secretion of nucleosides (9, 32, 39) .
Numerous studies with isolated membranes and renal cell lines have demonstrated functional nucleoside transporters in mammalian kidneys or cells derived therefrom. Separate concentrative transport activities for purine and pyrimidine nucleosides were shown with brush border membrane vesicles (BBMV) from rat kidney (28) , and other studies with BBMV from renal cortex from rats (29) (30) (31) , rabbits (55), and cows (56) , also demonstrated concentrative sodium-dependent transport activities.
NBMPR-binding sites were detected on rat kidney membranes (54) and a basolateral NBMPR-sensitive nucleoside transport activity was shown in rabbit basolateral membrane vesicles (55). The opossum kidney OK1 (12) and pig kidney LLC-PK1 (16) cell lines exhibit equilibrative transport activities and small components of concentrative transport activities.
Nucleoside transporters have been demonstrated in human kidney by both functional studies and molecular cloning. Functional studies with human kidney BBMV revealed a single concentrative sodium-dependent nucleoside transport activity with pyrimidine-nucleoside selective characteristics (18) except that guanosine was also a permeant. Two concentrative transporter proteins (hCNT1, hCNT2) were identified by molecular cloning using cDNAs prepared from human kidney (19, 43, 44, 52) . It is uncertain whether or not the third human concentrative transporter (hCNT3) is also present in human kidney since hCNT3 mRNA levels detected in renal tissues in a commercial northern blot were very low (41).
Asymmetric distribution of various transporters on cell surfaces is thought to determine the net absorption or secretion of nucleosides across epithelia. For example, it has been proposed that absorption of nucleosides in the gastrointestinal tract is accomplished by sodium-dependent concentrative transporters on apical surfaces and equilibrative transporters on basolateral surfaces, Page 4 of 40 resulting in the net transport of dietary nucleosides from the intestinal lumen into blood (8) . A similar hypothesis has been proposed for renal reabsorption of nucleosides by proximal tubules (35) .
Information on the distribution and localization of nucleoside transporter proteins in human kidney will facilitate understanding of renal nucleoside reabsorption and excretion processes. In this paper we describe results from studies of five of the seven known human nucleoside transporters (hENT1/2, hCNT1/2/3) in human kidney sections by reverse transcription polymerase chain reaction (RT-PCR) and immunoblotting. Although mRNA encoding all five transporters was observed, hENT1 and hCNT3 were the major proteins detected by immunoblotting with monoclonal antibodies directed against each of the five human transporter proteins. The anatomic locations of hENT1 and hCNT3 were determined in human kidney sections, respectively, by immunohistochemistry and immunofluorescence using established marker proteins to identify proximal tubules, loops of Henle and collecting ducts.
Equilibrium binding studies were undertaken with the potent and highly specific inhibitor of hENT1, NBMPR, to confirm the presence of hENT1 on apical surfaces of proximal tubular membranes. water served as negative controls. Identities of amplified products were confirmed by DNA sequencing of excised bands. PCR amplification positive controls were performed on plasmid (pYpGE15) constructs that contained either hENT1, hENT2, hCNT1, hCNT2 or hCNT3 fulllength inserts produced as previously described (51, 57) .
Preparation of crude membranes
Crude membranes from kidney cortical and medulla samples were prepared as described previously using tissue from four kidneys (47) . Tissues pieces were minced into small pieces and washed thoroughly with PBS pH 7.4 to remove blood. They were then suspended in icecold homogenization buffer (10 mM Tris-HCl, pH 7.5, 250 mM sucrose, 1 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride) and homogenized. Homogenates were centrifuged (320 g, 10 min) at 4°C, and supernatants were recentrifuged (15,000 g, 30 min) at 4°C. Pellets consisting of crude plasma membrane fractions were suspended in homogenization buffer and snap-frozen in liquid nitrogen before storage at -80°C until further use.
Immunoblotting analyses
Yeast membranes were prepared by a method described previously (50) . Briefly, yeast cells producing recombinant hENT1, hENT2, hCNT1, hCNT2 or hCNT3 proteins were grown, cells were lysed and membrane fractions were obtained by centrifugation of lysates at 120000 g for 60 min. The resulting membrane pellets were resuspended in buffer that contained protease inhibitors. The samples were either used immediately or frozen at -80 °C.
Crude membranes (20 µg protein each) from kidney tissues prepared as described above were subjected to SDS-polyacrylamide gel electrophoresis, after which proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Immobilon-P, Millipore, Bedford, MA, USA).
The PVDF membranes were incubated overnight at 4°C in 0.2% Tween-20, Tris-buffered saline containing 5% (w/v) skim milk powder (blocking buffer) followed by incubation with monoclonal antibodies against either hENT1, hENT2, hCNT1, hCNT2 or hCNT3 in blocking buffer for 1 h at room temperature. PVDF membranes were washed three times with blocking buffer and incubated with anti-mouse horseradish peroxidase secondary antibodies in blocking buffer for 1 h and washed extensively with blocking buffer to remove unbound antibodies.
Immunoreactive bands were visualized on x-ray film by enhanced chemiluminescence with horseradish peroxidase conjugated anti-mouse IgG antibodies and cyclic diacylhydrazides (ECL, Amersham Pharmacia Biotech, Uppsala, Sweden). Protein content was determined with the BioRad protein assay kit (Bio-Rad, Hercules, CA, USA).
Isolation of brush border membranes (BBMV)
BBMV from kidney cortex were prepared as described previously (5) . The final pellet of BBMV was resuspended in 300 mM mannitol, 5 mM Tris-HCl buffer pH 7.4, and passed through a fine needle to produce uniform membrane vesicles. All procedures were carried out at 4°C. Alkaline phosphatase (EC 3.1.3.1) activity was monitored using the Sigma alkaline phosphatase activity kit (Sigma-Aldrich, St. Louis, MO, USA) to quantify enrichment of BBMV and protein concentrations were determined using the BioRad protein assay kit. Portions of BBMV suspensions were snap-frozen in liquid nitrogen and stored at -80°C until further use. 
NBMPR binding
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Immunohistochemistry
Immunohistochemistry was performed as described elsewhere (11, 33, 34, 45) . Sections To identify segments positive for hENT1, consecutive sections were stained for defined tubule markers as previously described (22) . Each tissue section that was stained for tubule markers was flanked by a consecutive tissue section that was stained for hENT1. Sections were incubated with appropriate dilutions of primary antibodies (protein µg/ml): 10 µg/ml for antihENT1 monoclonal antibodies; 0.3 µg/ml for anti-PNRA monoclonal antibodies; 4 µg/ml for anti-AQP2 polyclonal antibodies; 0.2 µg/ml for anti-H + ATPase polyclonal antibodies; and 0.5 µg/ml for anti-THP monoclonal antibodies. Controls for monoclonal antibodies were isotype mouse anti-IgG antibodies and controls for polyclonal antibodies were rabbit anti-IgG antibodies at appropriate dilutions. Slides with anti-hENT1 antibodies were incubated in a humidified chamber overnight at 4°C, whereas slides with all other antibodies were incubated for 30 min at room temperature. Sections were then rinsed with PBS, immersed in PBS for 5 min, incubated with goat anti-mouse dextran conjugate or goat anti-rabbit dextran conjugate (DAKO Envision+) for 30 min, followed by soaking in PBS. DAKO diaminobenzidine liquid chromagen was placed on samples for 5 min and rinsed with tap water, after which, slides were soaked in 1% sections stained for specific tubule markers and hENT1 were collected so that the images obtained contained the same kidney tubules from consecutive sections.
Immunofluorescence staining
Kidney tissue specimens were embedded in Tissue-Tek® O.C.T compound (Sakura Finetek, Torrance, CA, USA) and snap-frozen in a dry ice-methanol bath. Cryostat sections (4-6 µm thick) were picked up on glass microscope slides and dried at room temperature overnight, followed by a 10-min fixation in acetone, and then air-dried for 5 min. Immunofluorescence staining of frozen kidney tissue sections was performed in a humidified atmosphere using 3MM
paper soaked in PBS in a rectangular Petri dish. The tissue was blocked for 30 min with 2% goat serum in PBS. hCNT3 monoclonal antibodies (50 µg/ml) in PBS were added to the tissue for 30 min at room temperature and washed three times with PBS (5 min/wash) using a Coplin jar.
AlexaFluor 488 goat anti-mouse IgM secondary antibodies (8 µg/ml) PBS were added to slides for 30 min at room temperature, stored in a dark environment, and then washed three times with PBS (5 min/wash). All slides were mounted with a # 1 cover slip using Mowiol mounting medium with -phenylenediamine as anti-fade and with 1 µg/ml 4'-6-diamidino-2-phenylindole.
To test anti-hCNT3 antibodies for specificity, 500 µg/ml of the antigenic peptide REHTNTKQDEEQVTVEQDSPRNREH or a non-related peptide were added to anti-hCNT3
antibody solutions and incubated for 30 min at room temperature before they were applied to tissue sections. Sections from four different kidneys were used for staining with hCNT3 antibodies in immunofluorescence studies.
Culture of human renal proximal tubule cells (hRPTCs)
hRPTCs were isolated by the enzyme dissociation method using a collagenase-DNAase 
Nucleoside uptake assays
Uridine uptake by confluent hRPTCs was measured as described previously (14) 
Results: Expression of mRNAs encoding hENTs and hCNTs in human kidney
To assess expression of nucleoside transporter genes in human kidney cortex and medulla, RT-PCR was performed using specific primers for hENT1/2 and hCNT1/2/3. As resolved by agarose gel electrophoresis and visualized by ethidium bromide staining, reaction products of predicted sizes were amplified from first strand cDNA for the five transporter types.
RT-PCR analysis of kidney samples from two different individuals identified transcripts for hENT1, hENT2, hCNT1, hCNT2, and hCNT3 in both cortex and medulla (Fig 1) . Genomic DNA contamination was not detected in RT-negative PCR reactions. DNA sequencing of excised bands confirmed the identity of amplified products. The same results were obtained in experiments from human kidney cortex and medulla samples from four additional individuals (data not shown).
Identification of hENTs and hCNTs by immunoblotting
Immunoblotting analyses with monoclonal antibodies specific for hENT1, hENT2, hCNT1, hCNT2 or hCNT3 were carried out with crude membrane fractions (20 µg protein each) prepared from human kidney cortex and medulla of three different individuals. Membrane fractions prepared from yeast producing either recombinant hENT1, hENT2, hCNT1, hCNT2 or hCNT3 proteins were also loaded as controls. The results for hENT1 and hCNT3 are shown in Fig 2. Major immunoreactive proteins at 45-48 and < 90 kD, corresponding to hENT1 and hCNT3, respectively, were detected in both cortex and medulla in all three samples (Fig 2) .
hCNT3 migrated lower than 90 kD whereas the recombinant nucleoside transporter protein controls migrated at slightly higher than 90 kD. In contrast, little, if any, hENT2, hCNT1 or hCNT2 was detected at the same protein levels (although the yeast controls were positive), indicating that hENT2, hCNT1 or hCNT2 were either absent or below limits of detection of immunoassays (data not shown). The lower molecular weight immunoreactive bands in the hENT1 (top) panel could have been due to incomplete glycosylation of the hENT1 protein or to proteolysis during storage of membrane fractions.
Localization of hENT1 and hCNT3 in human kidney
Since the immunoblotting results suggested that hENT1 and hCNT3 proteins were more abundant than hENT2, hCNT1 or hCNT2 in kidney tissue membranes, localization studies were undertaken to assess the anatomic distribution of hENT1 and hCNT3. hENT1 was examined using immunohistochemistry methods and hCNT3 using immunofluorescence methods since results from immunohistochemistry studies of hCNT3 were not clear-cut, possibly due to the effects of paraformaldehyde fixation of kidney (20) . Frozen tissue sections fixed with acetone postsectioning retained good immunoreactivity for hCNT3. Kidney samples from four different individuals yielded similar results for both transporters.
Validation of the specificity of the antibodies
Specificity of the anti-hENT1 and anti-hCNT3 antibodies was confirmed in peptide competition assays. Antibodies against hENT1 stained apical surfaces of tubules (Fig 3 a) whereas pre-adsorption of anti-hENT1 antibodies with excess immunogenic peptides corresponding to amino acids 254-271 of hENT1 abolished positive staining (Fig 3 c) and preadsorption with excess hCNT3-specific immunogenic peptides corresponding to amino acids 45-69 of hCNT3 had no effect (Fig 3 b) . Similarly, the specificity of hCNT3 immunofluorescent staining (Fig 3 d) was verified by retention of staining when anti-hCNT3 antibodies were preadsorbed with excess hENT1 peptides (Fig 3 e) , and loss of staining when anti-hCNT3
antibodies were pre-adsorbed with hCNT3 antigenic peptides (Fig 3 f) .
Proximal tubules
Immunohistochemistry and immunofluorescence staining was undertaken to compare distributions of nucleoside transporter proteins hENT1 and hCNT3, which had been detected by immunoblotting of crude membranes. Positive staining for hENT1 was detected in proximal tubules of the kidney cortex (Fig 4 a, b) . PNRA strongly labeled brush border regions of proximal tubules (Fig 4 c) , and a comparison of the PNRA and hENT1 staining in consecutive kidney sections of the same specimens revealed that hENT1 was concentrated in PNRA-defined proximal tubules. The background staining observed in the proximal tubular lumen was likely due to the presence of cellular debris from brush borders of proximal tubules. Positive staining for hCNT3 in proximal tubules was demonstrated by confocal microscopy with double immunofluorescence staining with antibodies against hCNT3 (Fig 4 e) and PNRA (Fig 4 f) and counterstaining with 4'-6-diamidino-2-phenylindole, which stains nuclei. hCNT3 staining was intense towards apical aspects of membranes with some intracellular staining as well (Fig 4 h ).
Panel l shows the negative control in these studies. The merged images (Fig 4 g, h) showed colocalization of the red and green signals of PNRA and hCNT3, respectively, on apical surfaces of proximal tubules although some intracellular staining of hCNT3 was also present.
Thick ascending loop of Henle
THP is present in the thick ascending loops of Henle and immunohistochemistry with antibodies against hENT1 and THP in consecutive kidney sections of the same specimens, showed moderate apical and basolateral hENT1 surface staining (Fig 4 i, j) in THP-defined (Fig   4 k) thick ascending loops of Henle . Double immunofluorescence staining with antibodies against hCNT3 (Fig 4 m) and THP (Fig 4 n) and counterstaining with DAPI showed localization of CNT3 in THP-stained tubules (Fig 4 o, p) and apical surface staining of hCNT3 (Fig 4 m, o, p) in thick ascending loops of Henle.
Collecting ducts
Immunohistochemistry with antibodies against hENT1 and two markers of collecting ducts (AQP2, H + -ATPase) in consecutive tissue sections of the same specimens showed moderate apical and basolateral surface localization of hENT1 (Fig 5 a, b and i, j) in collecting duct cells identified by both AQP2 (Fig 5 c) and H + -ATPase staining (Fig 5 k) . In contrast, double immunofluorescence staining with antibodies against hCNT3 (Fig 5 e, m ) and either AQP2 (Fig 5 f) or H + -ATPase (Fig 5 n) showed no detectable staining of hCNT3 in collecting ducts defined by either AQP2 (Fig 5 f) or H + -ATPase (Fig 5 n) , indicating absence of hCNT3 in collecting ducts. 
NBMPR binding analyses

Identification of NT activities in primary cultures of proximal tubule cells
Since immunostaining experiments showed that hENT1 and hCNT3 were present in human kidney proximal tubules, experiments were undertaken to functionally identify hENT1 and hCNT3 in hRPTCs. Normal regions of human kidney tissues obtained from patients undergoing nephrectomy for localized renal cell carcinoma were used to generate hRPTCs by established methods (4) . hRPTCs were subcultured up to eight generations in serum-free media on collagen-coated surfaces under conditions for which they retained phenotypic characteristics of human kidney proximal tubules including: (i) expression of brush border enzymes acid phosphatase, alkaline phosphatase, and -glutamyl transferase, (ii) the presence of sodiumdependent glucose transport activity, and (iii) the responsiveness to parathyroid hormone (1).
Confluent monolayers of hRPTCs that were used for uridine uptake studies developed tight junctions as assessed by anti-ZO-1 staining (data not shown), confirming that the cultures were polarized.
To identify concentrative and equilibrative nucleoside transport processes present in hRPTCs, uptake of radiolabeled uridine was measured under conditions that eliminated either equilibrative or concentrative nucleoside transport processes. Uptake mediated by hCNTs was assessed in sodium-containing buffer with 200 µM dilazep to inhibit equilibrative transport activity. Under these conditions, uptake of 1 µM [ 3 H]uridine was completely inhibited by 10 mM uridine, 1 mM thymidine, or 1 mM inosine (Fig 6A) , indicating that the dominant concentrative nucleoside transporter in hRPTCs was the broadly selective hCNT3. The higher uptake (p <0.001) observed in the presence of dilazep than in its absence presumably reflected blockade by dilazep of uridine efflux via hENT-mediated processes. hENT-mediated uptake of 1 µM 
Discussion:
Functional studies in animal kidney cells and in membrane preparations from animal and human kidneys have shown multiple sodium-dependent and sodium-independent transport systems in renal epithelia (18, 29, 31, (54) (55) (56) . Although CNTs seem to be restricted to apical membranes of polarized cells (18, 53) , the location of ENTs is controversial and hENT1 and hENT2 (es and ei activities since hENT1 and hENT2 were not cloned at that time) have been reported in apical (48), basolateral (55) or in both apical and basolateral membranes (12) Both ENTs and CNTs have been suggested to play important roles in renal tubular reabsorption and secretion of nucleosides and nucleoside drugs in humans (35) . However, to date, there is no information regarding the precise anatomic locations of nucleoside transporter proteins in human kidney. The present study was undertaken to determine the abundance and distribution of nucleoside transporters in renal cortex and medulla of normal portions of human kidneys removed from patients with renal carcinoma.
As an initial step, we evaluated expression of mRNA encoding various nucleoside transporters using RNA isolated from cortex and medulla of human kidney specimens from five different patients. RT-PCR analysis of RNA samples identified transcripts for hENT1, hENT2, hCNT1, hCNT2, and hCNT3 in both cortex and medulla of all specimens, indicating expression of all five transporter genes. Crude membranes from both cortex and medulla from four different kidney specimens were prepared and evaluated by immunoblotting using transporter-specific antibodies. hENT1 and hCNT3 were detected in all four samples, whereas little, if any, hENT2, hCNT1 or hCNT2 was detected, indicating that the latter were either absent or below limits of detection of the immunoassays. The abundance of hENT1 and hCNT3 varied between samples and between the cortex and medulla of each sample. Subsequent immuno-localization in renal cortex and medulla of hENT1 and hCNT3
proteins, respectively, in paraffin sections by immunohistochemistry or frozen sections by immunofluorescence was carried out using monoclonal antibodies specific for either hENT1 or hCNT3. In normal human kidney, PNRA staining is localized to apical surfaces of proximal tubules (22) , and in this work hENT1 staining in PNRA-defined proximal tubules of consecutive human kidney sections was observed only on apical surfaces. Prominent hCNT3 staining on apical surfaces of proximal tubules was evident in immunofluorescence studies and was colocalized with PNRA staining. In addition, some intracellular hCNT3 staining was observed in proximal tubules. In peptide pre-adsorption experiments, the immunogenic hENT1 and hCNT3 peptides completely abolished specific staining obtained with hENT1 and hCNT3 antibodies, respectively, whereas non-specific peptides were ineffective, demonstrating that the staining observed was epitope-specific. Although transcripts for all three hCNTs have been found in human kidney (this work and (15, 43, 44, 46, 52) ), the results presented here identified hCNT3 as the major CNT in human kidney;
hCNT1 and hCNT2, if present, were not detected in immunoblotting experiments with crude membrane preparations. hCNT1/2 have Na + -nucleoside coupling ratios of 1:1 and hCNT3 has a Na + -nucleoside coupling ratio of 2:1 (42, 46). A physiological implication of this difference in coupling ratio is that hCNT3 is capable of utilizing the electrochemical Na + -gradient to generate a trans-membrane nucleoside concentration ~ 10-fold higher than either hCNT1 or hCNT2 (15, 35) , suggesting that hCNT3 may be the key transporter involved in renal reabsorption of nucleosides. In addition, hCNT3 but not hCNT1/2 exhibits pH-dependent transport activity and thus can function as an H + -nucleoside co-transporter (46). The pH dependence of hCNT3 activity has important physiological relevance in the kidney since the lumen of the proximal renal tubule has an acidic pH (6) . In terms of permeant selectivity, the CNT3 isoform is functionally equivalent to CNT1 + CNT2.
To assess the nucleoside transport capacity of proximal tubules, uptake of [ prior to flux experiments, cells maintain polarity and grow with the brush border membrane facing upwards (27). The confluent hRPTCs used for uptake studies were polarized with apical tight junctions, so that measured fluxes were the result of uptake across brush border membranes.
hENT1 and hCNT3 were the major nucleoside transport activities in hRPTCs, consistent with the apical localizations of these transporters in proximal tubules shown in this work. A minor transport activity, probably mediated by hENT2, was also observed in hRPTC cultures.
In summary, our results using gene expression, protein abundance, inhibitor binding, immunohistochemistry, immunofluorescence and nucleoside uptake studies demonstrated hENT1 and hCNT3 to be the major nucleoside transporter proteins in human kidney. hENT1
was found on apical surfaces of proximal tubules and apical and basolateral surfaces of loop of Henle, distal tubules and collecting ducts, whereas hCNT3 was found on apical surfaces of proximal tubules, loop of Henle, and distal tubules. Although these results are consistent with a primary role for hCNT3 in reabsorption of nucleosides from apical surfaces of proximal tubules, they suggest that hENT1, which was observed on apical, but not basolateral, surfaces, may modulate reabsorption, raising the possibility that hENT2 (or some other transporter type) moves nucleosides across basolateral surfaces of proximal tubules during reabsorption,. Nucleoside transporters are likely involved in regulating renal levels of extracellular adenosine, which has a multiplicity of physiological and pathophysiological functions, including lowering of glomerular filtration rates, stimulating Na + reabsorption in proximal segments, and inhibiting Na + reabsorption in medullary segments (49) . 
DISCLOSURES
None
ACKNOWLEDGEMENTS:
We acknowledge the help of Dr. Gerry Todd and Dr. Michael Chetner, University of Alberta Hospital, in providing us with human nephrectomy specimens. 
